Lactate Dehydrogenase Levels in Immune Thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study is looking at the level of a substance called lactate dehydrogenase (LDH) in the blood of people with immune thrombocytopenia (ITP) to see if it can help understand the condition better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with immune thrombocytopenia (ITP) when you first found out about it.
- You cannot have any bone fractures or bone diseases.
- You cannot have any type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This study follows patients with immune thrombocytopenia (ITP) to learn more about the condition over time. ITP is a disorder where the immune system attacks platelets, which help blood clot. The goal is to better understand the disease and improve care.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This trial tests a new mRNA-based treatment for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The treatment aims to lower the immune attack and raise platelet counts.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.